Susan D. Wyrick - 13 Dec 2024 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role: Acting Chief Financial Officer and Principal Accounting Officer; Exhibit List: Ex. 24 - Power of Attorney
Signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick
Issuer symbol: SANA
Transactions as of: 13 Dec 2024
Transactions value $: -$17,344
Form type: 4
Date filed: 05 Dec 2025, 17:04
Previous filing: 15 Oct 2024
Next filing: 03 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wyrick Susan D.	Acting Chief Financial Officer and Principal Accounting Officer; Exhibit List: Ex. 24 - Power of Attorney	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE	/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick	2025-12-05	0001568605

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SANA	Common Stock	Options Exercise	$0	+10K	+6.23%	$0.00	170K	03 Jun 2025	Direct	F1, F2
transaction	SANA	Common Stock	Tax liability	-$5.96K	-2.57K	-1.51%	$2.32	168K	04 Jun 2025	Direct	F1
transaction	SANA	Common Stock	Options Exercise	$0	+10K	+5.85%	$0.00	181K	03 Dec 2025	Direct	F3
transaction	SANA	Common Stock	Tax liability	-$11.4K	-2.57K	-1.42%	$4.44	178K	04 Dec 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SANA	Restricted Stock Units	Award	$0	+3.4K		$0.00	3.4K	13 Dec 2024	Common Stock	3.4K		Direct	F1, F4, F5
transaction	SANA	Stock Option (Right to Buy)	Award	$0	+5.1K		$0.00	5.1K	13 Dec 2024	Common Stock	5.1K	$1.89	Direct	F1, F6
transaction	SANA	Restricted Stock Units	Options Exercise	$0	-10K	-50%	$0.00	10K	03 Jun 2025	Common Stock	10K		Direct	F1, F4, F7
transaction	SANA	Restricted Stock Units	Options Exercise	$0	-10K	-100%	$0.00	0	03 Dec 2025	Common Stock	10K		Direct	F4, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person.
F2	Includes 3,000 shares acquired on May 15, 2025 pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan (the "ESPP").
F3	Includes 3,000 shares acquired on November 14, 2025 pursuant to the ESPP.
F4	Each restricted stock unit represents a contingent right to receive one share of Sana common stock.
F5	The award vests as to 100% of the restricted stock units on December 13, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.
F6	The option vests as to 100% of the shares underlying the option on January 13, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.
F7	The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer; Exhibit List: Ex. 24 - Power of Attorney